Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | Transformed SCLC: emerging science on histologic subtype switching

Triparna Sen • 21 Mar 2022
ELCC 2022
Lung Cancer Non-Small Cell Lung Cancer Small Cell Lung Cancer Osimertinib

Small cell lung cancer (SCLC) transformation is a mechanism for acquired resistance to EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer (NSCLC). Triparna Sen, PhD, MS, BS, Memorial Sloan Kettering Cancer Center, New York, NY, outlines neuroendocrine transformation in lung cancer and it’s role in resistance. This interview took place during the virtual European Lung Cancer Congress 2022.

More from Triparna Sen

3:33
Molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer
Triparna Sen • 8 Aug 2022
2:11
Combination of WEE1 inhibition and immunotherapy provides promising preclinical data for SCLC
Triparna Sen • 21 Mar 2022
2:15
DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC
Triparna Sen • 21 Mar 2022
2:56
Current therapeutic landscape for small-cell lung cancer
Triparna Sen • 21 Mar 2022

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals